Clinical trials investigating various targeted therapies for CCA, including EGFR, HER2, VEGF, MET, CDK4/6, and pan-kinase inhibitors, have yielded disappointing results [131–138]. This evidence concerns the gene CDK4 and cholangiocarcinoma.